Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

Cecred hair drops, containing keratin and biotin, are questioned for their effectiveness compared to proven treatments like minoxidil. Users express skepticism, suggesting deceptive marketing and the possibility of undisclosed use of other treatments like finasteride.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

A user has used finasteride for three years to maintain hair thickness and is considering adding minoxidil for temple recession. They report no side effects and are satisfied, while others discuss minoxidil's pros and cons and share hair treatment experiences.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

The user has been using finasteride, minoxidil, a dermastamp, and red light therapy for six months with no visible improvement since the three-month mark. Other users noted improvement, particularly in the left temple area, and encouraged the user to continue.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

The user has been using topical finasteride and minoxidil for two years with decent regrowth and recently added microneedling to their routine. They are questioning if the small hairs observed are new regrowth from microneedling or just vellus or miniaturized hairs.

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.

The conversation discusses whether to wait for Breezula while using topical minoxidil to avoid side effects from finasteride. It mentions Breezula's potential release in a year and its cost and long-term use considerations.

The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.

A 25-year-old shared progress on hair regrowth after 2.5 years of oral finasteride and over a year of inconsistent topical minoxidil use, noting significant density gains despite a long-standing receded hairline. The user emphasized patience, as noticeable improvements took about 18 months, and mentioned using Ascend brand finasteride and occasional Nizoral shampoo for seborrheic dermatitis.

The user is experiencing hair regrowth with oral minoxidil and dutasteride but still has fragile hairs that easily pluck out from the front center. Despite improvements, the user is concerned about the persistent fragility and shedding of these hairs.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. The conversation questions the effectiveness and patience required for these treatments.